Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltratio... () MD220 filter employs our proprietaryMi...)

Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products

Date:6/6/2008

) MD220 filter employs our proprietary Mid-Dilution diafiltration technology and is sold and distributed throughout Europe. The Nephros HDF system removes a range of harmful substances more effectively than existing ESRD treatment methods, particularly with respect to substances known collectively as "middle molecules." These molecules have been found to contribute to such conditions as dialysis-related amyloidosis, carpal tunnel syndrome, degenerative bone disease and, ultimately, mortality in the ESRD patient.

The Nephros line of water-filtration products incorporates its patented cold sterilization filtration technology, the Dual Stage Ultrafilter (DSU). The DSU has the capability to filter out bacteria, parasites, viruses and other biotoxins to produce biologically safe water, and its dual-stage design reduces the risk and facilitates detection of filter failure. With initial applications targeted at infection-control and potable water solutions, the DSU is in a pilot-use program at a major U.S. medical center and has been selected for further development by the U.S. Marine Corps.

For more information on Nephros, please visit Nephros' website at http://www.nephros.com.

Forward-Looking Statements

Statements in this news release that are not historical facts constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Such statements may be preceded by words such as "may," "plans," "expects," "believes," "hopes," "potential" or similar words. For such statements, Nephros claims the protection of the PSLRA.

Forward-looking statements are not guarantees of future performance, are based on assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond Nephros's control. Actual results may differ materially from the expectations contained in the forward-looking statements.
'/>"/>

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
2. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
3. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
4. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
5. Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
6. Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease
7. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
8. VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial
9. PacificGMP Completes GMP Product Fill for Trius Therapeutics
10. Cardinal Health Completes Enturia Acquisition
11. DaVita Clinical Research Completes Record Number of Renal Trials in 2007

Post Your Comments:

Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltratio...() MD220 filter employs our proprietaryMi...),Health